Aprea Therapeutics, Inc.
APRE
$0.90
-$0.03-3.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.30K | 1.80K | 118.10K | 162.50K | 205.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.30K | 1.80K | 118.10K | 162.50K | 205.80K |
| Cost of Revenue | 1.01M | 1.64M | 1.91M | 2.48M | 2.36M |
| Gross Profit | -1.01M | -1.64M | -1.79M | -2.32M | -2.15M |
| SG&A Expenses | 1.64M | 1.48M | 1.59M | 1.77M | 1.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.65M | 3.12M | 3.51M | 4.25M | 3.43M |
| Operating Income | -2.64M | -3.12M | -3.39M | -4.09M | -3.23M |
| Income Before Tax | -2.46M | -2.97M | -3.24M | -3.93M | -2.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.46M | -2.97M | -3.24M | -3.93M | -2.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.46M | -2.97M | -3.24M | -3.93M | -2.89M |
| EBIT | -2.64M | -3.12M | -3.39M | -4.09M | -3.23M |
| EBITDA | -2.64M | -3.11M | -3.38M | -4.08M | -3.22M |
| EPS Basic | -0.32 | -0.47 | -0.53 | -0.66 | -0.49 |
| Normalized Basic EPS | -0.20 | -0.29 | -0.33 | -0.41 | -0.30 |
| EPS Diluted | -0.32 | -0.47 | -0.53 | -0.66 | -0.49 |
| Normalized Diluted EPS | -0.20 | -0.29 | -0.33 | -0.41 | -0.30 |
| Average Basic Shares Outstanding | 7.69M | 6.37M | 6.08M | 5.99M | 5.95M |
| Average Diluted Shares Outstanding | 7.69M | 6.37M | 6.08M | 5.99M | 5.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |